Dog Mitral Valve Disease: Staging and Welfare Management

Mitral valve disease (MVD) is the most common heart disease in dogs, and proper staging using established guidelines helps owners and vets manage welfare through appropriate treatment at each disease stage.

Key Facts

MVD affects approximately 75% of Cavalier King Charles Spaniels by age 10, though all breeds can be affected.
The American College of Veterinary Internal Medicine (ACVIM) staging system classifies MVD from Stage A to Stage D.
Stage B1 dogs have a heart murmur but no symptoms and may not require medication.
Stage B2 dogs have cardiac enlargement on X-ray or echocardiogram and benefit from pimobendan to delay heart failure.
Stage C dogs have active or previous signs of congestive heart failure and require diuretics and other medications.
Stage D dogs have end-stage heart failure refractory to standard treatment.
Early-onset MVD in Cavaliers has a strong genetic component — breeding protocols aim to reduce prevalence.

Welfare Considerations

Staging MVD accurately is central to good welfare management. Undertreating dogs in Stage B2 means missing a proven window to delay heart failure onset, while overtreating Stage B1 dogs exposes them to unnecessary medication side effects. Regular veterinary monitoring with chest X-rays and echocardiography allows timely stage advancement. Quality of life in later stages can be significantly maintained through careful medication titration, dietary sodium restriction, and activity modification based on the individual dog's tolerance.

What You Can Do

Ensure dogs with heart murmurs are staged appropriately using echocardiography, not murmur grade alone.
Follow ACVIM 2019 guidelines for initiating pimobendan in Stage B2 MVD dogs.
Monitor Cavalier King Charles Spaniels from age 3 annually with cardiac auscultation.
Support Cavalier breeding health schemes that require both parents to be murmur-free at a minimum age before breeding.